AtriCure, Inc.
ATRCHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeHeadquartered within the healthcare sector, AtriCure, Inc. focuses on Medical Instruments & Supplies services and products. AtriCure, Inc. engages in the development, manufacture, and sale of devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral. At a $1.42B market cap, AtriCure, Inc. ranks as a small-cap company within healthcare. It offers Isolator Synergy Ablation System clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, a single-use disposable RF products for the treatment of cardiac arrhythmias; cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; and EPi-Sense Systems, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation.
Market Cap
$1.42B
Beta
1.28
P/E (TTM)
—
P/E (Fwd)
80.56
EPS (TTM)
$-0.10
EPS (Fwd)
$0.35
ROE
-1.0%
ROA
-0.3%
Cash
$146.2M
Total Debt
$74.9M
Free CF
$41.1M
52W Change
-18.7%
Annual Financials
Cash vs Debt
AtriCure, Inc. holds $146.2M in cash against $74.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company generates $41.1M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. ROE of -1.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $330.4M (2022) to $534.5M (2025), reflecting a 62% increase over the period.
As with any equity investment, ATRC carries market risk, sector-specific risk, and company-specific risk that investors should evaluate in the context of their own portfolios. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence AtriCure, Inc.'s trajectory.